» Articles » PMID: 11903030

Biochemical Diagnosis of Pheochromocytoma: Which Test is Best?

Overview
Journal JAMA
Specialty General Medicine
Date 2002 Mar 21
PMID 11903030
Citations 280
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Diagnosis of pheochromocytoma depends on biochemical evidence of catecholamine production by the tumor. However, the best test to establish the diagnosis has not been determined.

Objective: To determine the biochemical test or combination of tests that provides the best method for diagnosis of pheochromocytoma.

Design, Setting, And Participants: Multicenter cohort study of patients tested for pheochromocytoma at 4 referral centers between 1994 and 2001. The analysis included 214 patients in whom the diagnosis of pheochromocytoma was confirmed and 644 patients who were determined to not have the tumor.

Main Outcome Measures: Test sensitivity and specificity, receiver operating characteristic curves, and positive and negative predictive values at different pretest prevalences using plasma free metanephrines, plasma catecholamines, urinary catecholamines, urinary total and fractionated metanephrines, and urinary vanillylmandelic acid.

Results: Sensitivities of plasma free metanephrines (99% [95% confidence interval [CI], 96%-100%]) and urinary fractionated metanephrines (97% [95% CI, 92%-99%]) were higher than those for plasma catecholamines (84% [95% CI, 78%-89%]), urinary catecholamines (86% [95% CI, 80%-91%]), urinary total metanephrines (77% [95% CI, 68%-85%]), and urinary vanillylmandelic acid (64% [95% CI, 55%-71%]). Specificity was highest for urinary vanillylmandelic acid (95% [95% CI, 93%-97%]) and urinary total metanephrines (93% [95% CI, 89%-97%]); intermediate for plasma free metanephrines (89% [95% CI, 87%-92%]), urinary catecholamines (88% [95% CI, 85%-91%]), and plasma catecholamines (81% [95% CI, 78%-84%]); and lowest for urinary fractionated metanephrines (69% [95% CI, 64%-72%]). Sensitivity and specificity values at different upper reference limits were highest for plasma free metanephrines using receiver operating characteristic curves. Combining different tests did not improve the diagnostic yield beyond that of a single test of plasma free metanephrines.

Conclusion: Plasma free metanephrines provide the best test for excluding or confirming pheochromocytoma and should be the test of first choice for diagnosis of the tumor.

Citing Articles

Biogenic amine testing in the South African public health care system.

Legg-ESilva D, Cave E, Snyman T, Currin S, Kone N, Prigge K Pract Lab Med. 2025; 44:e00457.

PMID: 39968348 PMC: 11833340. DOI: 10.1016/j.plabm.2025.e00457.


Metastatic Malignant Paraganglioma of Rare Sites Failed on Conventional Treatments Demonstrating Beneficial Response to Lu-DOTATATE PRRT.

Edamadaka Y, Bal M, Rane S, Parghane R, Basu S World J Nucl Med. 2025; 24(1):83-92.

PMID: 39959153 PMC: 11828642. DOI: 10.1055/s-0044-1791819.


Management of concurrent aortic stenosis and pheochromocytoma.

Kolyvas P, Ramadurai G, Al Hawasli H, Kolyvas C BMJ Case Rep. 2025; 15(9).

PMID: 39901381 PMC: 9453997. DOI: 10.1136/bcr-2022-250472.


Multiplexed Dilute-and-Shoot Liquid Chromatography-Multiple-Reaction Monitoring Mass Spectrometry Clinical Assay for Metanephrines and Catecholamines in Human Urine.

Qasrawi D, Pimenta A, Petrotchenko E, Eintracht S, Borchers C Metabolites. 2025; 15(1).

PMID: 39852373 PMC: 11767516. DOI: 10.3390/metabo15010030.


Why do patients with pheochromocytomas/paragangliomas exhibit significantly inconsistent elevation of catecholamines and their metabolites? a large Chinese cohort study.

Zhou Y, Chen Y, Zhang W, Cui Y, Li T, Wang Y Endocrine. 2024; 87(3):1267-1275.

PMID: 39537959 DOI: 10.1007/s12020-024-04094-7.